Related Experiment Video
Updated: Jun 17, 2026

Gene-targeted Random Mutagenesis to Select Heterochromatin-destabilizing Proteasome Mutants in Fission Yeast
Published on: May 15, 2018
A Simple and Affordable Method to Create Nonsense Mutation Clones of p53 for Studying the Premature Termination Codon
Chia-Chi Chen1,2,3,4, Ruo-Yu Liao5, Fang-Yu Yeh1
1School of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.
Abstract:
(1) Background: A premature termination codon (PTC) can be induced by a type of point mutation known as a nonsense mutation, which occurs within the coding region. Approximately 3.8% of human cancer patients have nonsense mutations of p53. However, the non-aminoglycoside drug PTC124 has shown potential to promote PTC readthrough and rescue full-length proteins. The COSMIC database contains 201 types of p53 nonsense mutations in cancers. We built a simple and affordable method to create different nonsense mutation clones of p53 for the study of the PTC readthrough activity of PTC124. (2) Methods: A modified inverse PCR-based site-directed mutagenesis method was used to clone the four nonsense mutations of p53, including W91X, S94X, R306X, and R342X. Each clone was transfected into p53 null H1299 cells and then treated with 50 μM of PTC124. (3) Results: PTC124 induced p53 re-expression in H1299-R306X and H1299-R342X clones but not in H1299-W91X and H1299-S94X clones. (4) Conclusions: Our data showed that PTC124 more effectively rescued the C-terminal of p53 nonsense mutations than the N-terminal of p53 nonsense mutations. We introduced a fast and low-cost site-directed mutagenesis method to clone the different nonsense mutations of p53 for drug screening.
Insights
The drug PTC124 can help restore full-length p53 protein by promoting premature termination codon (PTC) readthrough. It is more effective for C-terminal p53 nonsense mutations than N-terminal ones.
Area of Science:
- Molecular Biology
- Cancer Genetics
- Drug Discovery
Background:
- Nonsense mutations create premature termination codons (PTCs), leading to truncated proteins.
- Approximately 3.8% of human cancers harbor p53 nonsense mutations.
- The drug PTC124 shows potential for promoting PTC readthrough and restoring protein function.
Purpose of the Study:
- To develop a cost-effective method for creating p53 nonsense mutation clones.
- To investigate the PTC readthrough activity of PTC124 on different p53 nonsense mutations.
Main Methods:
- A modified inverse PCR-based site-directed mutagenesis method was employed.
- Four p53 nonsense mutations (W91X, S94X, R306X, R342X) were cloned.
- Clones were transfected into p53-null H1299 cells and treated with PTC124.
Main Results:
- PTC124 induced p53 re-expression in clones with C-terminal mutations (R306X, R342X).
- PTC124 did not induce p53 re-expression in clones with N-terminal mutations (W91X, S94X).
Conclusions:
- PTC124 demonstrates differential efficacy based on the location of p53 nonsense mutations.
- PTC124 is more effective at rescuing C-terminal p53 nonsense mutations.
- A rapid and affordable site-directed mutagenesis method was established for p53 nonsense mutation cloning and drug screening.
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
piRNA - Piwi-interacting RNAs
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle

